The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Open accessAbstract
Cancer immunotherapies have shown substantial clinical activity for a subset of patients with epithelial cancers. Still, technological platforms to study cancer T-cell interactions for individual patients and understand determinants of responsiveness are presently lacking. Here, we establish and validate a platform to induce and analyze tumor-specific T cell responses to epithelial cancers in a personalized manner. We demonstrate that co-cultures of autologous tumor organoids and peripheral blood lymphocytes can be used to enrich tumor-reactive T cells from peripheral blood of patients with mismatch repair-deficient colorectal cancer and non-small-cell lung cancer. Furthermore, we demonstrate that these T cells can be used to assess the efficiency of killing of matched tumor organoids. This platform provides an unbiased strategy for the isolation of tumor-reactive T cells and provides a means by which to assess the sensitivity of tumor cells to T cell-mediated attack at the level of the individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, ex vivo coculture systems utilizing human peripheral blood mononuclear cells or tumor-infiltrating lymphocytes cocultured with patient-derived organoids provide valuable platforms to interrogate human-specific immune responses to phage-delivered antigens or immunotherapies [111–113]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 3×
“REAGENT or RESOURCE SOURCE IDENTIFIER Somatic Indel Detector (GATK) McKenna et al., 2010 https://software.broadinstitute.org/gatk/ snpEff, version 4.3 Cingolani et al., 2012 http://snpeff.sourceforge.net FlowJo version 10 https://www.flowjo.com/ ImageJ version 1.50i Schneider et al., 2012 https://imagej.nih.gov/ij/”
InfluentialAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 2×
“, 2012) and response to PD-1/PD-L1 blockade is restricted to approximately 20% of patients (Garon et al., 2015; Borghaei et al., 2015).”
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“The use of antibodies against immune checkpoints, such as CTLA-4 and PD-1/PD-L1, has shown clear clinical benefit for patients with advanced cancer, including melanoma, nonsmall-cell lung cancer (NSCLC), and mismatch repair-deficient (dMMR) colorectal cancer (CRC) (Larkin et al., 2015; Garon et al., 2015; Borghaei et…”
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,000
Du, Y., Yang, Y., Zheng, B., Zhang, Q., Zhou, S., & Zhao, L. (2025) · Oncogene · doi:10.1038/s41388-025-03273-8 · Cited by 4
“It is evident that co-culturing tumor organoids with immune cells induces a speci fi c immune response in T cells, and tumor-reactive T cells are expanded using an established ACT scheme, showing effective killing only in malignant tumors without attacking normal organoids [119].”
Highlighting recent achievements to advance more effective cancer immunotherapy
Belmonte, B., Spada, S., Allavena, P., Benelli, M., Bronte, V., Casorati, G., D’Ambrosio, L., Ferrara, R., Mondino, A., Nisticò, P., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03316-8 · Cited by 4
Cuvelier, G., Vermonden, P., Debisschop, P., Martin, M., Derouane, F., Liebisch, G., Ecker, J., Höring, M., Berlière, M., Bockstal, M. V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073375 · Cited by 4
“Future research should integrate advanced co-culture models incorporating cancer-associated fibroblasts (CAFs) or peripheral blood lymphocytes that preserve native TME elements to better understand JA therapeutic potential [32–36].”
Martínez, A. R., Giraldo-Ruiz, L., Ramos, M. C., Luque, I., Ribeiro, D., Postigo-Corrales, F., Alburquerque-González, B., Montoro‐García, S., Arroyo-Rodríguez, A. B., Conesa‐Zamora, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96457-x · Cited by 4
Studying tumour-specific T cell responses in 3D
Minton, K. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0058-7 · Cited by 4
A model for tumor–immune interaction
de Souza, N. (2018) · Nature Methods · doi:10.1038/s41592-018-0165-1 · Cited by 4
Popper, H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.40 · Cited by 4
“In addition, organ cultures cultivated together with their stroma/microenvironment opens such an insight into the immune mechanisms acting in a given carcinoma([123,124]).”
BackgroundDeveloping models of cholangiocarcinoma to close the translational gap in cancer research
Waddell, S. H., & Boulter, L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1882993 · Cited by 4
“Elegant PDO-TME co-cultures have recently been described for certain cancers [63,64]: Neal et al.”
Patient-Derived Organoids as a Stem Cell Model to Study Lung Cancer
Acosta-Plasencia, M., Castellano, J. J., Taylor, A. M., He, Y., Martı́nez, D., Monzó, M., Marrades, R. M., & Navarro, A. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_78 · Cited by 4
Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies
Schumacher, D., Regan, J. L., Przybilla, D., & Schäfer, R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_22 · Cited by 4
Kriplani, P. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220804142633 · Cited by 4
Base editing screens map mutations affecting IFNγ signalling in cancerPreprint
Coelho, M. A., Karakoç, E., Bhosle, S. G., Gonçalves, E., Burgold, T., Cooper, S., Cattaneo, C. M., Veninga, V., Consonni, S., Dinçer, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.29.486051 · Cited by 4
Self-citationKim, Y., Park, D., Lee, D. H., & Chung, C. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114642 · Cited by 3
Tumor Immune Engineering: Developing In Vitro Assays to Understand the Tumor–Immune Crosstalk
Iyer, R. N., Vartak, M., & Dey, T. (2025) · Advanced Biology · doi:10.1002/adbi.202400735 · Cited by 3
Eroğlu, G. Ö., Erol, A., Yaylım, İ., & Kuruca, S. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146876 · Cited by 3
“The in vitro co-culture model was designed with an immune cell-to-cancer cell ratio of 5:1, representing a condition in which the immune system is relatively inadequate [30,31].”
Development of organoids for drug research and tissue regeneration
Sun, J., Huang, S., Zhang, Q., Lei, L., & Nie, H. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100045 · Cited by 3
Mi, Z., Guan, H., Zhang, G., Li, D., Yu, Y., & Qu, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102619 · Cited by 3
“Seminal studies have demonstrated that such systems can preserve patient-specific T-cell receptor heterogeneity and that PD-1 blockade can enhance the killing of organoids derived from responsive patients, thus providing a direct functional readout that correlates with clinical outcomes [29,30].”
Small-cell lung cancer: anatomy of an immune-cold tumor
Millrine, D., Simpson, K., Blackhall, F. H., & Dive, C. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.11.011 · Cited by 3
Jesinghaus, M., Silva, M. G., Zaurito, A. E., Brunner, V., Saab, F., Rajamani, A., Krätzig, N. D. A., Bodenstein, N., Guillemant, R., Pohl, J., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03666-x · Cited by 4
Li, H., & Jin, C. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04951-4 · Cited by 3
“Therefore, to simulate a more complex TME, tumor organoids are co-cultured with diverse cell types, such as cancer-associated fibroblasts [67], tumor-reactive T cells [68], chimeric antigen receptor T cells, and macrophages, as well as combinations of these cell types with other cell types [66].”
Organoids: generation strategies, applications, and future challenges
Yin, H., Zhu, G., Hai-zhan, W., Yang, B., Wang, Z., & Xie, H. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05045-x · Cited by 3
“The emergence of co-culture systems that integrate immune cells with organoid models (called “immune organoids”) will further enhance our ability to study human-specific immune responses, the efficacy of cancer immunotherapy, and inflammatory pathology [178].”
Deconstructing cancer in 3D: models, mechanisms, and personalized solutions
Huang, Z., Duan, X., Ji, J., Cai, Q., Jin, P., Yu, B., & (48506), J. Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02704-8 · Cited by 5
“Co-culturing PDOs with autologous tumor-infiltrating lymphocytes or engineered T-cells allows for the real-time study of T-cell function, migration, and exhaustion [200].”
Abrahimi, P., Khan, J. F., Duren-Lubanski, A., Cai, W., Marouf, Y., Chen, N., Hirschhorn, D., Mammone, R. M., Miranda, I. C., Tallman, J. E., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20250699 · Cited by 3
Three-dimensional bioprinted organoids: advances and clinical translation
Zhang, Y., Huang, Z., Wang, B., Li, B. R., & Yang, Y. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag142 · Cited by 5
“Dijkstra et al. pioneered the coculture of tumor organoids with autologous peripheral blood lymphocytes, demonstrating successful generation of tumor-reactive T cells from both colo-rectal and non-small cell lung cancer patients [37].”
InfluentialTumor organoid-immune cell co-culture systems for precision oncology
Cai, L., Xiao, Y., Xie, F., & Yang, Z. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1865487 · Cited by 3
“Emile’s research team successfully achieved effective activation and expansion of tumor-reactive CD8 + T cells by co-culturing PDOs from mismatch repair-deficient colorectal cancer (dMMR CRC) and non-small cell lung cancer (NSCLC) with autologous PBMCs (Dijkstra et al., 2018).”
InfluentialOrganoids Models for the Study of Cell-Cell Interactions
Jiménez-Palomares, M., Cristobal, A., & Durán-Ruiz, M. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94562 · Cited by 3
Zhang, J., Ma, J., Xu, Y., Wu, Y., & Miao, M. (2023) · Talanta · doi:10.1016/j.talanta.2023.125292 · Cited by 3
Funk, C., Uhlig, N., Ruzsics, Z., Baur, F., Peindl, M., Nietzer, S., Epting, K., Vacun, G., Dandekar, G., Botteron, C., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200784 · Cited by 3
Microbiome-Based Formulations and Products and Their Therapeutic Implications
Sabir, M., Khan, K. A., Haider, I., Nisa, S., Shah, W. H., Sawar, S., & Saleem, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_17 · Cited by 3
Establishment and Characterization of Patient-Derived Oral Cancer Organoids
Harnischfeger, N., Szabó, L., & Kretzschmar, K. (2025) · Methods in molecular biology · doi:10.1007/7651_2024_594 · Cited by 3
TLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma
Hu, F., Hu, C., He, Y., Sun, Y., Han, C., Zhang, X., Yu, L., Shi, D., Sun, Y., Zhang, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13010151 · Cited by 5
“Recent studies have also begun to use TME as a predictive biomarker to identify patients who may benefit from immunotherapy [14].”
Generating tumor-specific T cells based on a head and neck cancer organoid for adoptive cell therapy
Chen, Y., Wang, S., Zheng, L., Chen, L., Xu, F., Guo, S., & Meng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573965 · Cited by 3
Tumor organoid and tumor-on-a-chip equipped next generation precision medicine
Zhao, W., Zhang, Z., Xu, S., Sun, X., Wang, Y., Ye, J., Wang, X., Gu, Z., & Chen, Z. (2025) · Biofabrication · doi:10.1088/1758-5090/ae0bb3 · Cited by 4
“In another research, it is proposed that co-culturing tumor organoids with peripheral blood lymphocytes could effectively stimulate the generation of tumor-specific T cells [74], offering a novel approach to alleviate the scarcity of immune cells in organoids [96].”
Brown, D. (2021) · Georgetown Scientific Research Journal · doi:10.48091/gsr.v1i2.20 · Cited by 3
Krog, R. T., de Miranda, N. F. C. C., Vahrmeijer, A. L., & Kooreman, N. G. (2021) · Cancers · doi:10.3390/cancers13225789 · Cited by 3
“To address this, novel models are not only required to provide insights into disease progression but also to be a tool for the discovery of new therapeutic targets and improved drug screening [15,16].”
BackgroundMohammadzadeh, S., Andalib, A., Khanahmad, H., & Esmaeil, N. (2023) · PubMed Central · Cited by 3
Jensen, G. L., Wang, X., Kuempel, J., Chen, Z., Yu, W., Palaskas, N. L., Sobieski, M. M., Nguyen, N. C., Powell, R. T., STEPHAN, C. C., et al. (2024) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2024.100122 · Cited by 3
“This well-established methodology partially mimics endogenous T cell activation by stimulating both the T cell receptor and coreceptor[57,58].”
Micati, D., Hlavca, S., Chan, W. H., & Abud, H. E. (2024) · BMC Biology · doi:10.1186/s12915-024-02092-9 · Cited by 3
Li, Y., Liao, W., & Sun, L. (2024) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.240187 · Cited by 4
“…PBMC NK 细胞等，而且肿瘤上皮及其基质成分可保持长达 30 d [21] 。此外，使用 ALI 法培养的 PDTO 还可以保留 原始肿瘤组织的 T 细胞受体 (T cell receptor ， TCR) 谱， 与原代癌组织中检测到的 T 细胞表型类似，表明 ALI 法培养的 PDTO 能够维持肿瘤的个体化免疫特征 [21] 。 Dijkstra 等 [25] 在评估免疫细胞 ALI 培养的肿瘤类器官 运输 [32-33] 动以及突触连接 [34] 。这揭示了宿主脉管系统能广泛浸 润到类器官中。但是体内移植成本高昂，且难以实 现高通量应用。研究 [35] 提出了一种新的体外血管化类”
Improving lung cancer tumor-infiltrating lymphocyte (TIL) manufacturing
Noldner, P., Zhou, Y., Lyniv, L., Conejo-Garcia, J. R., Antonia, S. J., & Shaz, B. H. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.07.001 · Cited by 3
Human Gastrointestinal Organoid Models for Studying Microbial Disease and Cancer
Chakrabarti, J. L., Dua-Awereh, M., Holokai, L. L., & Zavros, Y. L. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_223 · Cited by 3
Li, L., & Selaru, F. M. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.011 · Cited by 4
Song, Y., Wang, Y., Guan, A., Xue, J., Li, B., Huang, Z., Zheng, Z., Liang, N., Yang, Y., & Li, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1132940 · Cited by 3
“Researchers have reported that the co-culture of autologous peripheral blood lymphocytes with tumor organoids could induce the proliferation of tumor-reactive T cells (Dijkstra et al., 2018).”
BackgroundVries, N. L. D., van de Haar, J., Veninga, V., Chalabi, M., Ijsselsteijn, M. E., van der Ploeg, M., van den Bulk, J., Ruano, D., Haanen, J. B. A. G., Schumacher, T. N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.14.464229 · Cited by 3
Self-citationChemotherapy-induced intestinal injury promotes Galectin-9-driven modulation of T cell functionPreprint
Jansen, S. A., Cutilli, A., de Koning, C. C. H., van Hoesel, M., Sierra, L. S., Nierkens, S., Mokrý, M., Nieuwenhuis, E. E. S., Hanash, A. M., Mocholí, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.30.538862 · Cited by 3
Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like FeaturesPreprint
Mauri, G., Santorelli, L., Marasca, F., Ranzani, V., Crisafulli, G., Gasparotto, E., Puzzono, M., Baraibar, I., Salviati, L., Sogari, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7193450/v1 · Cited by 3
Picco, G., Rao, Y., Saedi, A. A., Walker, S. J., Bhosle, S. G., Lee, Y., Vieira, S. F., García-Casado, M. A., Garcia, G. V., May, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.23.695783 · Cited by 3
“As previously reported, CRC14a patient-derived organoids were established at the Netherlands Cancer Institute and kindly provided by the lab of Emile Voest (6,47).”
Patient-Derived Bladder Cancer Organoids: Model Construction and Drug Sensitivity Testing
Liu, R., Zhang, Y., & Zhou, Z. (2025) · Urologia Internationalis · doi:10.1159/000543983 · Cited by 2
Espinoza, A. S., McVicar, R. N., Finlay, D., Murad, R., Vuori, K., Grimmig, B. A., Bush, A., Smith, E., Mandel-Clausen, T., McGee, H. M., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42977 · Cited by 2
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
Nguyen, D., Schaller, M. A., Terracina, K. P., Xu, X., Pedro, D. I., Pepe, A., Urueña, J. M., Dupee, Z., Diodati, N. G., Smolchek, R. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640500 · Cited by 2
Gastric Cancer Treatment New Chapter: Organoid Models Leading Personalized Medicine
Meng, Y., Zhang, L., Yang, J., Wang, X., Zhu, M., & Kong, F. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00808-3 · Cited by 2
“The conventional cultivation process involves co-culturing immune cells with single-cell cancer organoids to establish tumor-specific T cells [56].”
From 3D culture to clinical decision-making: Systematic innovations in breast cancer organoids
Hu, M., Zhou, C., Li, M., & Zhao, J. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214528 · Cited by 2
Zheng, M., Yao, L., Jing, N., Wang, Y., Wang, X., & Yang, J. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s540143 · Cited by 2
“21,22 Importantly, metastasis is tough to evaluate with PDOs, as a tumor has both temporal and spatial invasiveness in the body.”
Strength through diversity: how cancers thrive when clones cooperate
Kuiken, M. C., Witsen, M., Voest, E. E., & Dijkstra, K. K. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70160 · Cited by 2
“However, recent advances in co-cultures of organoids with immune cells or stromal cells make it possible to functionally assess the interplay between different cell types [73,74].”
Self-citationFacilitating Personalized Immunotherapy with Interventional Radiology and Tumor Organoids
Tian, W., McKenney, A. S., & Zhan, C. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.08.038 · Cited by 2
Watterson, A., Picco, G., Veninga, V., Samarakoon, Y., Cattaneo, C. M., Vieira, S. F., Karakoç, E., Bhosle, S. G., Battaglia, T., Consonni, S., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102565 · Cited by 2
“…T cells more directly, we established a co-culture system for CRISPR-Cas9 KO screening comprising primary tumoroids derived from an MSI CRC (CRC-9) and autologous tumor-reactive T cells (predominantly CD8 + T cells 72 ) from peripheral blood mononuclear cells (STAR Methods 12,73–75 ).”
Self-citationResearch Advances and Disease Modeling in Respiratory Organoids
Chu, L., Chen, D., Jiang, S., Long, H., Liu, X., & Chen, Y. (2026) · Biomedicines · doi:10.3390/biomedicines14010221 · Cited by 2
“Through the co-culture of lung cancer organoids, autologous peripheral blood lymphocytes in a medium supplemented with interferon-γ , IL-2, and anti-PD-1 antibodies, there is a significant promotion of the expansion and enrichment of tumor-reactive CD4 + T cells and CD8 + T cells [165,166].”
Komahashi, M., Horaguchi, S., Tsuji, K., Hoshino, D., Kishida, T., Usui, K., Nakaigawa, N., Sato, S., Hamana, H., Kishi, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1729388 · Cited by 2
Kjølle, S., Presti, M., Roque, J. D. P., Bisgaard, L. H., Ramos, D. B., Zornhagen, K. W., Yde, C. W., Schmidt, A. Y., Verdys, P., Højgaard, M., et al. (2026) · Cells · doi:10.3390/cells15030259 · Cited by 3
“Indeed, PDO and TIL co-culture have previously been used to assess TIL reactivity and tumor killing [20,21]; however, there are no standardized methods for such setups.”
Jayathilaka, N. S., Maduwage, K. P., & Weththasinghe, A. V. (2026) · Toxin Reviews · doi:10.1080/15569543.2026.2623493 · Cited by 2
“…maturation in organoids (Homan et al. 2019) while automated platforms enable high-throughput manipulation and interrogation (Schuster et al. 2020). immune–organoid co-culture models now allow direct modeling of immunological interactions relevant to venom-gland biology (Dijkstra et al. 2018).”
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 2
“Unlike traditional cultures containing only tumor epithelium, PDO co-cultures can incorporate multiple immune cell types—including lymphocytes [188, 189], cytotoxic T lymphocytes (CTLs) [190, 191], dendritic cells (DCs) [192], natural killer (NK) [193] cells, and macrophages [194]—thereby…”
Sun, J., Ye, J., Chen, S., Yang, Z., Xu, G., Xue, Y., Ou, Z., Chen, X., & Wang, J. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00915-2 · Cited by 2
Organoid models: Regulations and prospects for the development of investigational new drugs
Li, H., Pan, Y., Zheng, Z., Lin, R., Pan, Y., Lin, L., Quan, M., Lu, H., Hu, Z., Zheng, M., et al. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004067 · Cited by 4
“[46,47] 51]”
Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening
Lago, C., Leva, G., Kool, M., Miele, E., & Tiberi, L. (2026) · Nature Protocols · doi:10.1038/s41596-026-01347-9 · Cited by 2
Alatawi, H., Nair, H. H., Raza, A., Vélez, E. D., Sharma, A. K., & Narayan, S. (2026) · Cancers · doi:10.3390/cancers18071166 · Cited by 2
“As regulatory agencies increasingly favor New Approach Methodologies (NAMs) and human-relevant data packages, it is expected that organoid-based evidence will play a central role in early-stage immunotherapy development [163,164].”
Augustin, A., Avignon, B., Boetsch, C., Breous-Nystrom, E., Broders, O., Cabon, L., Dernick, K., Durr, E., Eigenmann, M. J., Fischer, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736584 · Cited by 2
Functional vasculature in tumor organoids: Enabling precision medicine in oncology
Wu, W., Yao, G., Liu, Y., Zhang, L., Li, Z., Feng, X., Tao, S., Song, J., Kong, T., & Zhou, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189597 · Cited by 2
Su, Z., Li, H., Zhang, D., Shi, N., Song, C., Huang, Y., He, W., Yin, Z., & Li, L. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07706-0 · Cited by 3
“While foundational organ-oid-based enrichment studies have largely emphasized the expansion of MHC-restricted CD8+ clones [48, 51], our findings extend this paradigm by demonstrating that, in our patient-matched coculture system, repeated stimulation with autologous tumor organoids…”
Qi, J., & Yu, Y. (2026) · Cell Regeneration · doi:10.1186/s13619-026-00292-y · Cited by 2
“…on organoid technology, researchers have developed additional strategies, including organoid vascularization, organoid–immune cell co-culture, and organoid-on-a-chip systems, to better approximate the in vivo microenvironment (Dijkstra et al. 2018; Nwokoye and Abilez 2024; Zhao et al. 2024) (Fig.”
The gut microbiome in colorectal cancer: molecular paradigms and translational frontiers
Liu, Y., & Mei, D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1864299 · Cited by 2
Mun, H. B., Kwon, W. S., Park, C. H., Koo, H., Jang, J., Yoon, B. G., Park, J., Moon, Y. J., Lee, C., Jeung, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05006-4 · Cited by 2
Organoid technology in cancer research
Zhang, J., & He, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00505-5 · Cited by 3
“…in this field demonstrated that co-culture of patient-derived tumor organoids with autologous peripheral blood lymphocytes (PBLs) or TILs could generate tumor-reactive T cells, which specifically killed the tumor organoids while sparing normal tissue organoids from the same patient [156, 157].”
Wu, M., Xu, D., Dou, X., Zhou, Y., Lu, J., & Ge, Q. (2026) · Cell Signaling Inflammation & Disease · doi:10.1186/s44505-026-00004-y · Cited by 2
“Organoid-based co-culture systems integrating tumor cells with immune cells such as T lymphocytes, macrophages, or dendritic cells have emerged as promising platforms for evaluating immunotherapies [195].”
Oncolytic virotherapy meets the human organoid technology for pancreatic cancers
Fiorini, E., & Corbo, V. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102828 · Cited by 2
“Few experiences already exist of organotypic platforms that enable either short-term preservation of the native microenvironmental components [9] or refinement of culture conditions to accommodate the growth of stromal cells [10].”
BackgroundThe Application of the Tissue Microarray (TMA) Technology to Analyze Cerebral Organoids
Biunno, I., Paiola, E., & Blasio, P. D. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211025327 · Cited by 2
The application and research advances of organoids in clinical medicine
Mo, S., Guan, R., Long, Z., Cai, S., Peng, J., & GuoQiang, H. U. A. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0315 · Cited by 2
[Application and Research Progress of Lung Cancer Organoid in Precision Medicine for Lung Cancer].
Huang, Z., Li, B., Wang, Y., Xue, J., Wei, Z., Liang, N., & Li, S. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.106.07 · Cited by 2
“…LCO 培养基中添加基质细胞（包括内皮 细胞、免疫细胞和成纤维细胞）来实现与 TME 共培养模 型的构建，可以有效实现对细胞间的相互作用进行体外 观察和定量研究 [24] ，因此建立 LCO 与 TME 共培养模型有 利于更准确地探索肿瘤的发生发展机制和创新药物的研 发。 Dijkstra 等 [25] 研究证明了自体肿瘤类器官和外周血 淋巴细胞的共培养可以使用 NSCLC 患者外周血中富集 的肿瘤反应性 T 细胞，该研究为分离肿瘤反应性 T 细胞 提供了有效的策略。 Del Bufalo 等 [26] 发现与成纤维细胞共 培养的 LCO 生长得更快，表明基质成分的存在增强了肿…”
Surgical Considerations in Tumor-Infiltrating Lymphocyte Therapy: Challenges and Opportunities
Kirane, A., Lee, D., & Ariyan, C. E. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.11.015 · Cited by 2
Gastrointestinal cancer: Current status of preclinical research
Shahid, N., Hanif, S., Syed, M. A., Syed, H. K., Zahoor, A. F., Khan, I. U., Mohsin, N. U. A., Sonia, S., & Irfan, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31656-2.00015-3 · Cited by 2
Li, R. M., Dong, Q., Jian, H., & Bai, S. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100030 · Cited by 5
Experimental toolkit to study the oncogenic role of WNT signaling in colorectal cancer
Dash, P., Yadav, V. K., Das, B., & Satapathy, S. R. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189354 · Cited by 2
Bibliometric insights into breast cancer organoid chips: trends and emerging areas
Tian, Y., Chang, H., Cheng, M., Jin, J. J., Ye, X., & Zhao, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002560 · Cited by 2
Ma, L., Wang, X., Zhang, Q., Gao, Z., Ji, X., Li, Z., Li, Y., Zhang, P., Che, X., Sun, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218036 · Cited by 2
Bathini, M., Bocaniciu, D., Johnson, F. D., de Jong, R. C. P., Yu, F., Aloi, V. D., Kuiken, M. C., Mors, J. R., Giebel, L., Champagne, J., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09570-6 · Cited by 3
“Tumor resections were obtained from patients with microsatellite instable (MSI) colorectal cancer (CRC) within study NL48824.”
Self-citation3D modeling of the lung in health and disease
Surolia, R., Dsouza, K. G., & Antony, V. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824064-9.00016-2 · Cited by 2
Cancer: A Complex Problem Requiring Interdisciplinary Research
Yazdanpanah, N., Dochy, F. J. R. C., Darmstadt, G. L., Peters, G. J., Tsitlakidis, A., Aifantis, E. C., Cerdà, A., Comini, E., Brand, S., Gupta, M. K., et al. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_116 · Cited by 3
Recent advances in patient‐derived tumor organoids for reconstructing TME of head and neck cancer
Chen, L., Chen, Y., Ge, L., Zhang, Q., & Meng, J. (2024) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13532 · Cited by 2
Liver Organoid and T Cell Coculture Models Cytotoxic T Cell Responses against Hepatitis C VirusPreprint
Natarajan, V., Simoneau, C. R., Erickson, A. L., Meyers, N. L., Baron, J. L., Cooper, S., McDevitt, T. C., & Ott, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.10.455738 · Cited by 2
Li, S., Primeau, T. M., Highkin, M. K., Pratt, S. L., Tipton, A. R., Vemalapally, N., Monsey, J. D., Tao, Y., Luo, J. R., Hagemann, I. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.19.572069 · Cited by 3
TNFSF13 insufficiency disrupts human colonic epithelial cell-mediated B cell differentiationPreprint
Ma, X., Dawany, N. B., Kondo, A., Maurer, K., Karakasheva, T. A., Shraim, R., Williams, P. A., Parham, L. R., Simon, L. A., Danan, C. H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.23.614260 · Cited by 2
Buoyant mass reveals distinct T cell states predictive of checkpoint responsePreprint
Yu, J., Zhang, Y., Duquette, S. M., Kimmerling, R. J., Kostas, J. C., Lum, K. K., LaBella, R., Olçum, S., Vacha, M., Wasserman, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.26.615179 · Cited by 3
Ahmed, B. H., Zdyrski, C., Cheville, J. C., Rancilio, N. J., Abel, A. M., Wierson, W. A., McGill, J. L., Mochel, J. P., & Allenspach, K. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.235 · Cited by 1
Filippova, S. Y., Тимофеева, С. В., Межевова, И. В., Shalashnaya, E. V., Rozenko, L. Y., Av, S., & Novikova, I. A. (2023) · Russian Journal of Oncology · doi:10.17816/onco516562 · Cited by 1
Altered immunophenotypic expression in the peripheral bladder cancer immune landscape
Mackenzie, N. J., Zimmermann, K., Nicholls, C., Perera, O. M., Ngoo, A., Jeffery, P. L., Vela, I., Kenna, T., Williams, E. D., & Thomas, P. B. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12829 · Cited by 1
“10,11 12 PBMCs in this context may provide useful information regarding immune-related events at urological sites, 10,12,13 and there is increasing interest in studying the complex mechanisms by which immune alterations may modulate responses to various anticancer therapies.”
Individualized tumor-reactive T cells exhibit a potent anti-tumor response in prostate cancer
He, L., Jiao, N., Bao, X., Wu, Y., Qian, X., He, W., Zhen, H., Tang, L., Shao, H., Dong, Z., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102322 · Cited by 1
“Some studies have also reported the induction of reactive T cells using tumor tissue, which exhibited a good anti-tumor effect; however, the mechanism of action of these tumor reactive cells remains unclear [31,32].”
Decoding subclonal anti-tumor immunity
Chan, J. E., & Tammela, T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.018 · Cited by 1
Bridging the gap between bench and bedside: Organoid technology in colorectal cancer treatment
Tang, Y., Huang, Z., Li, Y. C., Li, B., Ma, L., Song, J., & Xue, L. (2025) · Cell organoid (Print) · doi:10.26599/co.2025.9410017 · Cited by 1
Cultures cellulaires en trois dimensions : applications à la biologie des cancers
Jubelin, C., Golias, M., Cochonneau, D., Muñoz-García, J., & Heymann, D. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.09.004 · Cited by 1
Ye, Y., Srisai, D., & Barsky, S. H. (2025) · Biomedicines · doi:10.3390/biomedicines13122890 · Cited by 1
Developing New Immunotherapy Approaches for Colorectal Cancer
Kelly, G., Nowlan, B., Tria, S. M., Nikkhoo, A., Bond, C., & Whitehall, V. (2025) · Cancers · doi:10.3390/cancers17243929 · Cited by 1
“Dijkstra et al. described the isolation of autologous lymphocytes from PBMCs of CRC patients to determine immunoactivity levels and assess the extent of immune mediated cancer cell killing at a personalised level [113,116].”
Influential
Metadata
- Authors
- Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., van Rooij, N., van Leerdam, M. E., Depla, A., Smit, E. F., Hartemink, K. J., de Groot, R., Wolkers, M. C., Sachs, N., Snaebjornsson, P., Monkhorst, K., Haanen, J., Clevers, H., Schumacher, T. N., & Voest, E. E.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Slotervaartziekenhuis (NL)
- Sanquin (NL)
- University Medical Center Utrecht (NL)
- Corresponding author
- Voest, Emile E.
- ORCID
- Dijkstra, Krijn K.
- Cattaneo, Chiara M.
- Weeber, Fleur
- Chalabi, Myriam
- van de Haar, Joris
- Fanchi, Lorenzo F.
- Slagter, Maarten
- van Rooij, Nienke
- van Leerdam, Monique E.
- Smit, Egbert F.
- Hartemink, Koen J.
- de Groot, Rosa
- Wolkers, Monika C.
- Sachs, Norman
- Monkhorst, Kim
- Haanen, John
- Clevers, Hans
- Schumacher, Ton N.
- Voest, Emile E.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 174
- Issue
- 6
- Pages
- 1586-1598.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6558289
- OpenAlex
- W2885650843
- Cited by
- 1,135
- References
- 47
- Citations by year
- 2026: 172 · 2025: 175 · 2024: 143 · 2023: 154 · 2022: 144 · 2021: 168 · 2020: 106 · 2019: 62 · 2018: 10
- FWCI
- 37.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- NWO Gravitation Program (NWO (2012-2022)
- KWF (HUBR2014-7006)
- KWF Queen Wilhelmina (NKI 2013-6122)
- ERC AdG SENSIT
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-reactive T cells, tumor organoids, peripheral blood lymphocytes, co-culture, personalized cancer immunotherapy, non-small cell lung cancer, epithelial cancers, T cell-mediated killing
- MeSH terms
- Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Interferon-gamma, Leukocytes, Mononuclear, Lung Neoplasms, Lymphocyte Activation, Male, Middle Aged, T-Lymphocytes, Tumor Cells, Cultured, Colorectal Neoplasms, Coculture Techniques, Cell Culture Techniques, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
